117 related articles for article (PubMed ID: 27470347)
1. Interferon β improves the efficacy of low dose cisplatin by inhibiting NF-κB/p-Akt signaling on HeLa cells.
Ethiraj P; Veerappan K; Samuel S; Sivapatham S
Biomed Pharmacother; 2016 Aug; 82():124-32. PubMed ID: 27470347
[TBL] [Abstract][Full Text] [Related]
2. Anti-proliferative effect of RCE-4 from Reineckia carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-κB activation.
Bai C; Yang X; Zou K; He H; Wang J; Qin H; Yu X; Liu C; Zheng J; Cheng F; Chen J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):573-84. PubMed ID: 26935715
[TBL] [Abstract][Full Text] [Related]
3. Dual apoptotic effect of Xrel3 c-Rel/NF-kappaB homolog in human cervical cancer cells.
Shehata M; Shehata M; Shehata F; Pater A
Cell Biol Int; 2004; 28(12):895-904. PubMed ID: 15566959
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of interferon-β on hepatocellular carcinoma HepG2 via Akt/STAT phosphorylation.
Ethiraj P; Veerappan K; Samuel S; Sivapatham S
Fundam Clin Pharmacol; 2015 Jun; 29(3):278-85. PubMed ID: 25773664
[TBL] [Abstract][Full Text] [Related]
5. PDCD6 additively cooperates with anti-cancer drugs through activation of NF-κB pathways.
Park SH; Lee JH; Lee GB; Byun HJ; Kim BR; Park CY; Kim HB; Rho SB
Cell Signal; 2012 Mar; 24(3):726-33. PubMed ID: 22142513
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer.
Banerjee S; Zhang Y; Wang Z; Che M; Chiao PJ; Abbruzzese JL; Sarkar FH
Int J Cancer; 2007 Feb; 120(4):906-17. PubMed ID: 17131310
[TBL] [Abstract][Full Text] [Related]
7. NF-κB signaling inhibition and anticancer activities of LLDT-246 on human colorectal cancer HCT-116 cells in vitro.
Li M; Wang X; Liu M; Qi X; Li J
Biomed Pharmacother; 2014 Jun; 68(5):527-35. PubMed ID: 24986326
[TBL] [Abstract][Full Text] [Related]
8. Alkaloids from Stephania venosa as Chemo-Sensitizers in SKOV3 Ovarian Cancer Cells via Akt/NF-κB Signaling.
Mon MT; Yodkeeree S; Punfa W; Pompimon W; Limtrakul P
Chem Pharm Bull (Tokyo); 2018; 66(2):162-169. PubMed ID: 29386467
[TBL] [Abstract][Full Text] [Related]
9. Concurrent blockade of the NF-kappaB and Akt pathways potently sensitizes cancer cells to chemotherapeutic-induced cytotoxicity.
He HN; Wang X; Zheng XL; Sun H; Shi XW; Zhong YJ; Huang B; Yang L; Li JK; Liao LC; Zhang L; Hu LN; Lin Y
Cancer Lett; 2010 Sep; 295(1):38-43. PubMed ID: 20207071
[TBL] [Abstract][Full Text] [Related]
10. Lycopene sensitizes the cervical cancer cells to cisplatin via targeting nuclear factor- kappa B (NF-κB) pathway.
Aktepe OH; Şahin TK; Güner G; Arik Z; Yalçin Ş
Turk J Med Sci; 2021 Feb; 51(1):368-374. PubMed ID: 32718121
[TBL] [Abstract][Full Text] [Related]
11. Theanine from tea and its semi-synthetic derivative TBrC suppress human cervical cancer growth and migration by inhibiting EGFR/Met-Akt/NF-κB signaling.
Liu J; Sun Y; Zhang H; Ji D; Wu F; Tian H; Liu K; Zhang Y; Wu B; Zhang G
Eur J Pharmacol; 2016 Nov; 791():297-307. PubMed ID: 27612630
[TBL] [Abstract][Full Text] [Related]
12. DNA-PKcs deficiency sensitizes the human hepatoma HepG2 cells to cisplatin and 5-fluorouracil through suppression of the PI3K/Akt/NF-κB pathway.
Fang Y; Chai Z; Wang D; Kuang T; Wu W; Lou W
Mol Cell Biochem; 2015 Jan; 399(1-2):269-78. PubMed ID: 25348361
[TBL] [Abstract][Full Text] [Related]
13. Concurrent blockade of NF-κB and Akt pathways potentiates cisplatin's antitumor activity in vivo.
Sun H; Zheng X; Wang Q; Yan J; Li D; Zhou Y; Lin Y; Zhang L; Wang X
Anticancer Drugs; 2012 Nov; 23(10):1039-46. PubMed ID: 22760211
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB.
Pozo-Guisado E; Merino JM; Mulero-Navarro S; Lorenzo-Benayas MJ; Centeno F; Alvarez-Barrientos A; Fernandez-Salguero PM
Int J Cancer; 2005 May; 115(1):74-84. PubMed ID: 15688415
[TBL] [Abstract][Full Text] [Related]
15. Acacetin (5,7-dihydroxy-4'-methoxyflavone) exhibits in vitro and in vivo anticancer activity through the suppression of NF-κB/Akt signaling in prostate cancer cells.
Kim HR; Park CG; Jung JY
Int J Mol Med; 2014 Feb; 33(2):317-24. PubMed ID: 24285354
[TBL] [Abstract][Full Text] [Related]
16. Akt is upstream and MAPKs are downstream of NF-κB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism.
Bava SV; Sreekanth CN; Thulasidasan AK; Anto NP; Cheriyan VT; Puliyappadamba VT; Menon SG; Ravichandran SD; Anto RJ
Int J Biochem Cell Biol; 2011 Mar; 43(3):331-41. PubMed ID: 20883815
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production.
Poma P; Notarbartolo M; Labbozzetta M; Sanguedolce R; Alaimo A; Carina V; Maurici A; Cusimano A; Cervello M; D'Alessandro N
Int J Oncol; 2006 Apr; 28(4):923-30. PubMed ID: 16525642
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anti-carcinogenic effect of interferon-β with cisplatin on human breast adenocarcinoma MDA MB231 cells.
Ethiraj P; Veerappan K; Doraisami B; Sivapatham S
Int Immunopharmacol; 2014 Nov; 23(1):222-8. PubMed ID: 25158919
[TBL] [Abstract][Full Text] [Related]
19. Cytokine-induced killer cells induce apoptosis and inhibit the Akt/nuclear factor-κB signaling pathway in cisplatin-resistant human glioma U87MG cells.
Cui Y; Yang F; He L
Mol Med Rep; 2015 Nov; 12(5):7027-32. PubMed ID: 26299434
[TBL] [Abstract][Full Text] [Related]
20. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R
Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
